Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Molecular and Cellular Mechanisms of Cancers: Multiple Myeloma 2020
share announcement

Molecular and Cellular Mechanisms of Cancers: Multiple Myeloma 2020

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 11858

Special Issue Editor

Prof. Ramon Garcia Sanz

E-Mail Website
Guest Editor
Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
Interests: molecular genetics; multiple myeloma; Hodgkin’s lymphoma; Waldenström macroglobulinemia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multiple Myeloma (MM) is a neoplastic disorder characterized by the accumulation of plasma cells that produce a monoclonal immunoglobulin, accompanied by bone destruction, hypercalcemia, medullar insufficiency, or renal impairment. Recent advances in technology, such as the new high-throughput genomic methodologies, gene editing methods, next-generation flow and mass cytometry, and novel imaging techniques, have generated a huge amount of information about myeloma pathogenesis. Accordingly, many new cellular and molecular insights have emerged in myeloma, which makes a comprehensive review of the current biology of the disease compulsory.

This Special Issue of Cells will focus on the current molecular and cellular mechanisms of multiple myeloma. It will include reviews and original reports focused on cell ontogeny, signaling pathways, microenvironment, and genomics of myeloma cells. New diagnostic and monitoring possibilities will also be covered, including blood, bone marrow, and skeletal evaluation of the disease, especially for the evaluation of minimal residual disease, the new goal for multiple myeloma therapy. Finally, the evaluation of potential new targets and mechanisms of resistance will also be considered in the issue, providing information towards possible cures for this disease.

We are pleased to present this Special Issue of Cells, with the hope that it will be of value to all interested in myeloma.

Prof. Ramon Garcia Sanz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • normal and myelomatous plasma cell ontogeny
  • signaling pathways in myeloma
  • microenvironment in plasma cell dyscrasias
  • genetic abnormalities in multiple myeloma
  • clues for tumor progression: from normal B-cells to plasma cell myeloma
  • blood biopsies in monoclonal gammopathies
  • minimal residual disease in multiple myeloma
  • bone disease in MM
  • new targets in the therapeutics of MM
  • biological background of drug resistance in multiple myeloma

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1749 KiB  
Article
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
by Esperanza M. Algarín, Dalia Quwaider, Francisco J. Campos-Laborie, Andrea Díaz-Tejedor, Pedro Mogollón, Elena Vuelta, Montserrat Martín-Sánchez, Laura San-Segundo, Lorena González-Méndez, Norma C. Gutiérrez, Ramón García-Sanz, Teresa Paíno, Javier De Las Rivas, Enrique M. Ocio and Mercedes Garayoa
Cells 2021, 10(3), 559; https://doi.org/10.3390/cells10030559 - 04 Mar 2021
Cited by 4 | Viewed by 2791
Abstract
BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). Interleukin 6, produced by mesenchymal stromal cells (MSCs), has been shown to modify the expression of anti-apoptotic proteins [...] Read more.
BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). Interleukin 6, produced by mesenchymal stromal cells (MSCs), has been shown to modify the expression of anti-apoptotic proteins and their interaction with the pro-apoptotic BIM protein in MM cells. In this study, we assess the efficacy of S63845 and venetoclax in MM cells in direct co-culture with MSCs derived from MM patients (pMSCs) to identify additional mechanisms involved in the stroma-induced resistance to these agents. MicroRNAs miR-193b-3p and miR-21-5p emerged among the top deregulated miRNAs in myeloma cells when directly co-cultured with pMSCs, and we show their contribution to changes in MCL-1 and BCL-2 protein expression and in the activity of S63845 and venetoclax. Additionally, direct contact with pMSCs under S63845 and/or venetoclax treatment modifies myeloma cell dependence on different BCL-2 family anti-apoptotic proteins in relation to BIM, making myeloma cells more dependent on the non-targeted anti-apoptotic protein or BCL-XL. Finally, we show a potent effect of the combination of S63845 and venetoclax even in the presence of pMSCs, which supports this combinatorial approach for the treatment of MM. Full article
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Multiple Myeloma 2020)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 1632 KiB  
Review
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
by Ignacio J. Cardona-Benavides, Cristina de Ramón and Norma C. Gutiérrez
Cells 2021, 10(2), 336; https://doi.org/10.3390/cells10020336 - 05 Feb 2021
Cited by 45 | Viewed by 8715
Abstract
Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago remain major prognostic factors. In recent years, the introduction of cutting-edge genomic methodologies has enabled the extensive deciphering of genomic events in MM. Although none of the alterations newly discovered [...] Read more.
Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago remain major prognostic factors. In recent years, the introduction of cutting-edge genomic methodologies has enabled the extensive deciphering of genomic events in MM. Although none of the alterations newly discovered have significantly improved the stratification of the outcome of patients with MM, some of them, point mutations in particular, are promising targets for the development of personalized medicine. This review summarizes the main genetic abnormalities described in MM together with their prognostic impact, and the therapeutic approaches potentially aimed at abrogating the undesirable pathogenic effect of each alteration. Full article
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Multiple Myeloma 2020)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop